GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety Amid Development of GEO-CM04S1 for Vulnerable Populations

GeoVax Labs, Inc. reaffirmed its commitment to rigorous, science-based evaluation of vaccine safety following discussions by federal officials at the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices meeting regarding reports of adverse events related to COVID-19 vaccination. The clinical-stage biotechnology company emphasized the importance of transparent pharmacovigilance and ongoing review of safety data for all vaccines, supporting systems like the Vaccine Adverse Event Reporting System designed to detect potential signals requiring further independent analysis.

The company's investigational multi-antigen COVID-19 vaccine, GEO-CM04S1, is based on the Modified Vaccinia Ankara viral vector platform with a decades-long history of safe use in various populations including immunocompromised individuals, pregnant women, and pediatric populations. Currently evaluated in multiple ongoing Phase 2 clinical trials, GEO-CM04S1 targets patients with hematologic cancers resulting in significantly weakened immune systems that do not adequately respond to current authorized COVID-19 vaccines. To date, the vaccine has demonstrated a favorable safety profile under independent Data and Safety Monitoring Boards oversight and encouraging immune response within immune-compromised patients.

David Dodd, Chairman and CEO of GeoVax, stated that the company's mission focuses on developing vaccines that address the needs of populations most at risk from infectious diseases, particularly immunocompromised individuals for whom existing vaccine options may provide insufficient protection. The company remains committed to transparent science, thorough safety monitoring, and collaboration with regulatory authorities as it works to deliver this solution. Ongoing clinical trials are designed with robust pharmacovigilance frameworks and long-term follow-up to ensure comprehensive assessment of safety and efficacy.

The development of GEO-CM04S1 represents a critical advancement for vulnerable populations who have limited protection from current vaccine options. For immunocompromised patients, particularly those with hematologic cancers, the availability of an effective vaccine could significantly reduce COVID-19-related morbidity and mortality. The vaccine's multi-antigen approach and MVA platform technology may provide broader and more durable protection compared to existing options. The company's emphasis on rigorous safety monitoring aligns with growing public awareness about vaccine safety and the need for transparent communication regarding adverse event reporting.

GeoVax's commitment to evidence-based vaccine development comes at a time when vaccine safety discussions are increasingly prominent in public health conversations. The company's approach to pharmacovigilance and its focus on vulnerable populations addresses important gaps in current pandemic preparedness. As clinical trials continue, the potential success of GEO-CM04S1 could establish new standards for vaccine development for immunocompromised patients and influence future approaches to pandemic response. For more information about the company's clinical trials and updates, visit https://www.geovax.com.